This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Registration Savings Deadline Expires In

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center
Book Your Pass
Menu
Book
Key Sessions
William Schaut
Regulatory Requirements for CAR T Starting Materials
Janssen Pharmaceuticals, Inc
James Bolling
Development of a Robust Allogeneic CAR T Manufacturing Process Using the ARCUS® Genome Editing Technology
Precision BioSciences
keyboard_arrow_right

Day 3 - EST/EDT (Eastern Daylight, GMT-4)

keyboard_arrow_leftSearch & Filter
search

Day 3 - EST/EDT (Eastern Daylight, GMT-4)

search
10:15am - 10:45am30 mins
Gene Edited Ex Vivo Therapy
Benefits of Editing in Ex Vivo Cell Therapy
  • Devyn Smith - Chief Executive Officer, Arbor Biotechnologies
10:45am - 11:15am30 mins
Gene Edited Ex Vivo Therapy
Development of a Robust Allogeneic CAR T Manufacturing Process Using the ARCUS® Genome Editing Technology
  • James Bolling - Associate Director, Process Development, Precision BioSciences
11:15am - 11:45am30 mins
Gene Edited Ex Vivo Therapy
Non-Viral Editing of Primary Cells Using Flowfect®Tx, A New Transfection Technology Platform from Kytopen
  • Ta-Chun Hang - Director of Biology, Kytopen
12:55pm - 1:00pm5 mins
Gene Edited Ex Vivo Therapy
Chairperson's Opening Remarks
    1:00pm - 1:30pm30 mins
    Gene Edited Ex Vivo Therapy
    Commercial Manufacturing Readiness for a Autologous Gene Edited Cell Therapy
    • Ken Green, PhD - Snr Dir, MSAT-Commercial Manufacturing & Supply Chain, Vertex
    1:30pm - 2:00pm30 mins
    Gene Edited Ex Vivo Therapy
    Phase Appropriate Assay Qualification and Robustness for Cell Therapy RFI (Release for Infusion) Products
    • Akshata Ijantkar - Senior Scientist, Bristol Myers Squibb
    2:00pm - 2:30pm30 mins
    Gene Edited Ex Vivo Therapy
    Scientific Track Presentation
      3:30pm - 4:00pm30 mins
      Gene Edited Ex Vivo Therapy
      Scale Up of Allogeneic Programmes - GMP Grade Raw Material Considerations
        4:00pm - 4:30pm30 mins
        Gene Edited Ex Vivo Therapy
        TBC
        • Lior Raviv - Vice President, Pluristem Therapeutics Inc.
        4:30pm - 5:00pm30 mins
        Gene Edited Ex Vivo Therapy
        Scientific Sponsored Track Presentation
          Day 2
          NextDay 4
          Filter
          Streams
          Clear
          Formats
          Choose Day